Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase 2 trial

BACKGROUND: We performed a phase II trial of pembrolizumab in patients with NSCLC or melanoma with untreated brain metastases to determine the activity of PD-1 blockade in the CNS. Interim results were previously published, and we now report an updated analysis of the full NSCLC cohort. METHODS: Thi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Oncol
Main Authors: Goldberg, Sarah B., Schalper, Kurt A., Gettinger, Scott N., Mahajan, Amit, Herbst, Roy S., Chiang, Anne C., Lilenbaum, Rogerio, Wilson, Frederick H., Omay, Sacit Bulent, Yu, James, Jilaveanu, Lucia, Tran, Thuy, Pavlik, Kira, Rowen, Elin, Gerrish, Heather, Komlo, Annette, Gupta, Richa, Wyatt, Hailey, Ribeiro, Matthew, Kluger, Yuval, Zhou, Geyu, Wei, Wei, Chiang, Veronica, Kluger, Harriet M.
Format: Artigo
Jezik:Inglês
Izdano: 2020
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7380514/
https://ncbi.nlm.nih.gov/pubmed/32251621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30111-X
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki